These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36190331)

  • 1. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2.
    Finn RS; Yau T; Hsu CH; De Toni EN; Goyal L; Galle PR; Qin S; Rao S; Sun F; Wang C; Widau RC; Zhu AX
    Oncologist; 2022 Dec; 27(12):e938-e948. PubMed ID: 36190331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
    Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
    J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2.
    Kudo M; Galle PR; Llovet JM; Finn RS; Vogel A; Motomura K; Assenat E; Merle P; Brandi G; Daniele B; Okusaka T; Tomášek J; Borg C; Dadduzio V; Morimoto M; Pracht M; Jen MH; Drove Ubreva N; Widau RC; Shinozaki K; Yoshikawa R; Zhu AX
    Liver Int; 2020 Aug; 40(8):2008-2020. PubMed ID: 32279446
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
    Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
    Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
    Zhu AX; Nipp RD; Finn RS; Galle PR; Llovet JM; Blanc JF; Okusaka T; Chau I; Cella D; Girvan A; Gable J; Bowman L; Wang C; Hsu Y; Abada PB; Kudo M
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32817068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
    Chau I; Peck-Radosavljevic M; Borg C; Malfertheiner P; Seitz JF; Park JO; Ryoo BY; Yen CJ; Kudo M; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Okusaka T; Bowman L; Cui ZL; Girvan AC; Abada PB; Yang L; Zhu AX
    Eur J Cancer; 2017 Aug; 81():17-25. PubMed ID: 28591675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of Ramucirumab
    Maesaka K; Sakamori R; Yamada R; Tahata Y; Ohkawa K; Oshita M; Tamura S; Hagiwara H; Mita E; Yakushijin T; Inada M; Kodama T; Hikita H; Tatsumi T; Takehara T
    Anticancer Res; 2021 Apr; 41(4):2187-2192. PubMed ID: 33813432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of ramucirumab for various treatment lines in real-world practice of patients with advanced hepatocellular carcinoma.
    Kanogawa N; Ogasawara S; Maruta S; Iino Y; Obu M; Ishino T; Ogawa K; Yumita S; Iwanaga T; Unozawa H; Nakagawa M; Fujiwara K; Sakuma T; Fujita N; Kojima R; Kanzaki H; Koroki K; Kobayashi K; Inoue M; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Nakamoto S; Muroyama R; Chiba T; Itobayashi E; Koma Y; Azemoto R; Kato J; Kato N
    BMC Gastroenterol; 2023 Mar; 23(1):70. PubMed ID: 36906542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials.
    Llovet JM; Singal AG; Villanueva A; Finn RS; Kudo M; Galle PR; Ikeda M; Callies S; McGrath LM; Wang C; Abada P; Widau RC; Gonzalez-Gugel E; Zhu AX
    Clin Cancer Res; 2022 Jun; 28(11):2297-2305. PubMed ID: 35247922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study.
    Shao G; Bai Y; Yuan X; Chen X; Gu S; Gu K; Hu C; Liang H; Guo Y; Wang J; Yen CJ; Lee VH; Wang C; Widau RC; Zhang W; Liu J; Zhang Q; Qin S
    EClinicalMedicine; 2022 Dec; 54():101679. PubMed ID: 36247923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
    Sugimoto R; Motomura K; Ooho A; Aratake Y; Ueda A; Senju T; Tanaka Y; Yada M; Tanaka K; Kuwano A; Morita Y; Nagasawa S; Ooe M; Mutsuki T; Yoshimoto T; Yamashita N; Nakashima M; Hioki T; Koyanagi T; Higuchi N; Nakamura T; Harada S; Tanaka M; Tada S; Satoh T; Uchimura K; Kuniyoshi M; Nakamuta M; Kohjima M;
    Intern Med; 2022; 61(21):3157-3164. PubMed ID: 36328582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml.
    Zheng H; Qin Z; Qiu X; Zhan M; Wen F; Xu T
    J Med Econ; 2020 Apr; 23(4):347-352. PubMed ID: 31856618
    [No Abstract]   [Full Text] [Related]  

  • 16. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.
    Hatooka M; Kawaoka T; Aikata H; Inagaki Y; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Awai K; Masaki K; Waki K; Kohno H; Kohno H; Moriya T; Nagaoki Y; Tamura T; Amano H; Katamura Y; Chayama K
    BMC Cancer; 2018 Jun; 18(1):633. PubMed ID: 29866075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
    Kudo M; Hatano E; Ohkawa S; Fujii H; Masumoto A; Furuse J; Wada Y; Ishii H; Obi S; Kaneko S; Kawazoe S; Yokosuka O; Ikeda M; Ukai K; Morita S; Tsuji A; Kudo T; Shimada M; Osaki Y; Tateishi R; Sugiyama G; Abada PB; Yang L; Okusaka T; Zhu AX
    J Gastroenterol; 2017 Apr; 52(4):494-503. PubMed ID: 27549242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ramucirumab: A Review in Hepatocellular Carcinoma.
    Syed YY
    Drugs; 2020 Feb; 80(3):315-322. PubMed ID: 32034692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.